在ST11 CRKP中,blaKPC-2放大和一种新的mrcA突变驱动了sefiderocol异阻力

Yuxuan Liu1, Hanxu Hong1, QianBin Dai2

  • 1Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China; School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, PR China.

概括

耐卡巴尼姆的Klebsiella pneumoniae (CRKP) 可以通过blaKPC-2放大和mrcA突变,发展出对 cefiderocol (FDC) 的异阻力. 这种双重机制可能导致治疗失败,并在临床环境中低估了耐药性.